Endo USA, Inc. Issues Recall of One Lot of Clonazepam Orally Disintegrating Tablets Due to Mislabeling: Incorrect Strength on Product Carton

GENERIC DRUG APPROVALS – July 2024
July 1, 2024
FDA Approves Femlyv Orally Disintegrating Birth Control Pill
July 22, 2024
GENERIC DRUG APPROVALS – July 2024
July 1, 2024
FDA Approves Femlyv Orally Disintegrating Birth Control Pill
July 22, 2024

July 16, 2024 - Endo, Inc announced that one of its operating subsidiaries, Endo USA, Inc., is voluntarily recalling one lot of Clonazepam Orally Disintegrating Tablets, USP (C-IV) 0.25mg tablets, which may also appear as Clonazepam Orally Disintegrating Tablets, USP (C-IV) 0.125mg tablets 60-count pack to the consumer level.

The product lot is being recalled due to mislabeling where an incorrect strength appears on the cartons of some packs to show the product strength as 0.125mg and not 0.25mg due to an error at a third-party packager. The blister strips inside the product pack reflect the correct strength of 0.25mg.

This recall impacts the following product lot:

  • See below image of correct carton label: Clonazepam Orally Disintegrating Tablets, USP 0.25mg 60-count carton, lot 550147301, expiration date August 2026
  • See below image of incorrect carton label: Clonazepam Orally Disintegrating Tablets, USP 0.125mg 60-count carton, lot 550147301, expiration date August 2026

(Note: No BeneCard PBF members were affected by this recall.)

Source: FDA

Read More at Drugs.com